Theralase Technologies Inc (TSV: TLT )
0.2850
-0.0150
(-5.00%)
Streaming Delayed Price
Updated: 3:59 PM EST, Feb 14, 2025
Add to My Watchlist
Press Releases about Theralase Technologies Inc
Theralase(R) Demonstrates Effective Treatment of Herpes
February 12, 2025
Theralase(R) Launches Three New Clinical Study Sites in USA
December 09, 2024
Theralase(R) Launches New Clinical Study Site in Canada
December 05, 2024
Theralase(R) Release’s 3Q2024 Financial Statements
November 27, 2024
Theralase(R) Closes Non-Brokered Private Placement
November 15, 2024
Theralase(R) Extends Warrants
November 12, 2024
Theralase(R) Provides Update on Bladder Cancer Clinical Study
October 07, 2024
Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options
September 24, 2024
Theralase(R) Extends Warrants
September 19, 2024
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
August 28, 2024
Theralase(R) Release’s 2Q2024 Financial Statements
August 12, 2024
Rutherrin(R) Increases Efficacy of Chemotherapy
June 12, 2024
Ruvidar(TM) Enhances Efficacy of Cancer Drug
June 10, 2024
Theralase(R) Successfully Destroys Lung Cancer
June 06, 2024
Theralase(R) Technology Effective in Virus Inactivation
June 04, 2024
Theralase(R) Release's 1Q2024 Financial Statements
May 30, 2024
Theralase(R) Expands Clinical Team
May 02, 2024
Theralase(R) Granted Canadian Cancer Vaccine Patent
April 05, 2024
Theralase(R) Release's 4Q2023 Interim Financial Statements
March 27, 2024
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
